Eurofins Scientific Se · EURONEXT:ERF
Eurofins Scientific — 9M 2026 Earnings Presentation
13 slides from Eurofins Scientific's earnings presentation, Oct 21, 2026
Slide 1: 9M 2026 Trading Update
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2026. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: Key financial and operational highlights
Key financial and operational highlights Reported Revenues Key Highlights 9M 2026 Q3 2026 • Reported revenues in 9M 2026 totalled €5,614m, a 3.7% increase versus 9M 2025. Growth was €5,614m €1,913m driven by both organic growth and acquisitions, despite a -1.7% headwind from foreign exchange, and a
Slide 4: Revenue bridge
Revenue bridge (€m) 9M 2026: +3.0%1 • FX effect in 9M 2026 of -1.7% as the Q3 2026: +3.5%2 Euro strengthened against most currencies, broken down as: 16 5,614 o Q1: -4.8% headwind 59 o Q2: -0.9% headwind o Q3: +0.6% tailwind 160 109 • Organic revenue growth of +3.0% 5,472 (+2.9% including PWD adjust
Slide 5: Organic growth by activity, 9M 2026
Organic growth by activity, 9M 2026 Revenues (€m) Commentary Organic growth • North America had solid growth in both Food & Feed Testing and Environment Testing, with strong +3.0%1 5,614 demand in categories including dairy testing and PFAS testing 5,415 • Acquisition of Element’s Life Sciences Test
Slide 6: BioPharma acceleration in Q3 2026 was broad-based across multiple activities
BioPharma acceleration in Q3 2026 was broad-based across multiple activities (€m) BioPharma revenues BioPharma Product Testing and others1 1,042 1,020 1,039 • Mid-single digit growth for BioPharma Product Testing in Q3 2026 was led by North 1,000 1,010 America; with Europe growth also positive • Eur
Slide 7: Growth investments continued, with 22 acquisitions closed in 9M 2026
Growth investments continued, with 22 acquisitions closed in 9M 2026 Aggregated revenue of 9M 2026 acquisitions in FY 2025: >€210m (not including Element) North America Europe Rest of the World 7 acquisitions 14 acquisitions 1 acquisition Acquired: Acquired: Acquired: • Environment Testing businesse
Slide 8: Confirming mid-term and FY 2027 objectives, updating for FY 2026
Confirming mid-term and FY 2027 objectives, updating for FY 2026 • FY 2026 organic growth is likely to be below the previous mid-single-digit objective. This reflects the fact that market conditions have remained slower than normal after nine months, and that some expected clinical programmes will n
Slide 9: Q&A
Q&A CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2026]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 9
Slide 10: Appendix
Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2026]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 10
Slide 11: Breakdown of revenue by Operating Segment
Breakdown of revenue by Operating Segment 2024 2025 2026 As % €m Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 9M of total Sales 850 897 873 929 3,549 893 962 950 1,024 3,829 957 1,004 985 2,946 52% Europe Organic growth in 5.1% 3.5% 4.9% 2.9% 1.6% 3.6% 5.0% 3.3% 1.6% 2.3% 1.7% 1.9% the Core Business1 Sale
Slide 12: Breakdown of revenue by Area of Activity
Breakdown of revenue by Area of Activity 2024 2025 2026 As % €m Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 9M of total Sales 664 715 714 776 2,869 718 755 761 809 3,043 734 813 825 2,372 42% Life Organic growth in 7.2% 6.7% 7.4% 5.1% 6.1% 7.2% 5.9% 6.1% 4.2% 5.3% 3.7% 4.4% the Core Business1 Sales 489 5
Slide 13: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) Adjusted results – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. Separately disclosed items – include one-off costs from network expansion, integration and reorganisation, discontin